Replies to post #177752 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

I need to update the sticky, but double check the Compiled DD and add this:


Patent for treatment of Alzheimer's disease as a PROCESS:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145776628

New EEG techniques for Alzheimer's and other CNS disease under development, including AI:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145774113

[nidan7500]

Any chance you could please elaborate on the recent patent accomplishments?

I would suggest you review last weeks posts here. Many links and details available to include link to A2-73 AD PM high level discussion on the use of AI tool suite and collaborative agreement with Cognision EEG methods using tool suite (see FDA 510K141316) which infers strong class II medical device verification & validations (v&V) for the tool used as required by 21 CFR part 820 compliance requirements. The second Patent is also published by a poster showing an AVXL compound for pain treatments. It is suggested this may be used for acute pain, as appl. states. Bottom line. Patent process work is done and bodes well. It is not clear if the Rest of world sees the news as significant or if analysts have not yet figured out how the new FDA PM process-news cycle should be done.

It is also notable (IMO) that BIIB has published PR on a couple of partnering agreements suggesting new technology and AI. I have tried to look below the surface on bot deals and so far it's very dark.

[bas2020]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145420021